Compounds > fulvestrant
Page last updated: 2024-08-26

fulvestrant and leupeptins

fulvestrant has been researched along with leupeptins in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dutertre, M; Mancini, MA; Mancini, MG; O'Malley, BW; Patel, K; Smith, CL; Stenoien, DL1
Bell, DW; Coser, KR; Dean, KL; Hilario, PC; Hur, J; Isselbacher, KJ; Okimoto, RA; Shioda, T; Smith, SL; Tobey, EM1
Kang, L; Wang, ZY1
Marks, JR; McDonnell, DP; Wardell, SE1
Basile, I; Gallud, A; Garcia, M; Gary-Bobo, M; Maynadier, M1

Other Studies

5 other study(ies) available for fulvestrant and leupeptins

ArticleYear
FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent.
    Nature cell biology, 2001, Volume: 3, Issue:1

    Topics: Bacterial Proteins; Biological Transport; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dactinomycin; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; HeLa Cells; Histone Acetyltransferases; Humans; Leupeptins; Ligands; Luminescent Proteins; Microscopy, Fluorescence; Multienzyme Complexes; Nuclear Matrix; Nuclear Receptor Coactivator 1; Proteasome Endopeptidase Complex; Protein Structure, Tertiary; Receptors, Estrogen; Tamoxifen; Transcription Factors; Transcription, Genetic

2001
Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein.
    Cancer research, 2006, Oct-15, Volume: 66, Issue:20

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Estradiol; Fulvestrant; Gamma Rays; Gene Expression Regulation, Neoplastic; Humans; Leupeptins; Membrane Proteins; Mitochondrial Proteins; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Receptors, Estrogen; RNA, Messenger; Transcription, Genetic; Tumor Suppressor Protein p53

2006
Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-alpha36.
    Journal of cellular and molecular medicine, 2010, Volume: 14, Issue:6B

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Genome, Human; Humans; Isothiocyanates; Leupeptins; Phosphorylation; Signal Transduction

2010
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.
    Biochemical pharmacology, 2011, Jul-15, Volume: 82, Issue:2

    Topics: Cells, Cultured; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Humans; Insulin-Like Growth Factor I; Leupeptins

2011
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
    Oncology reports, 2016, Volume: 36, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Leupeptins; MCF-7 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen

2016